Aurobindo Pharma Ltd has lined up about seven products for launch during the present quarter in the US market.
According to Robert Cunard, Chief Executive Officer, Aurobindo Pharma, USA, the seven products were essentially fourth quarter approvals. “Just due to timing and preparation of inventory and preparing for customer requirements, these will be launched in the present quarter,’’ he said in a recent earnings call.
The product portfolio comprises some key products, including Celecoxib, Tramadol ER. The US revenues of Aurobindo have been growing at a compounded annual growth rate of 52 per cent. Its share in the total revenue has gone up from 39 per cent in 2014-15 to 44 per cent at ₹6,144 crore in 2015-16. Aurobindo now has about 398 filings and 251 approved. Out of 251, 215 have got final approvals and can be launched. The company has 160 products in the market. During the last financial year, Aurobindo had launched 28 products. It expects approvals and launches to be more this year in comparison with last year.
The product portfolio mix has been expanding towards high value products. It has ‘strong’ pipeline of sterile products, including ophthalmic, respiratory, oncology, hormones and penems.
In terms of business strategy, Aurobindo is in the process of consolidating its presence in Europe and improve its position among top 10 players in each market. It has operations in nine countries with full-fledged sales forces and support infrastructure. It is also expanding to new geographies such as Poland and Czech Republic.
Aurobindo’s scrip gained 1.56 per cent on the BSE on Tuesday to close at ₹769.15.